



Final Appraisal Recommendation

Advice No: 0316 – February 2016

Oseltamivir (Tamiflu®) 30 mg, 45 mg and 75 mg capsules, and 6 mg/ml powder for oral suspension

Limited submission by Roche Products Ltd

Recommendation of AWMSG

Oseltamivir (Tamiflu®) is recommended for use within NHS Wales for the treatment of infants less than 1 year of age including full term neonates who present with symptoms typical of influenza, when influenza virus is circulating in the community. Efficacy has been demonstrated when treatment is initiated within two days of first onset of symptoms.

Additional note(s):

- Please refer to the Summary of Product Characteristics for the full licensed indication.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 2800), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

| | |
|---|--------------------|
| Marketing authorisation holder on first issue | Roche Products Ltd |
| Date of first issue | February 2016 |
| Last reviewed | April 2019 |

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 0316:
oseltamivir (Tamiflu®) 30 mg, 45 mg and 75 mg capsules, and 6 mg/ml powder for oral suspension.
February 2016.

